Chimeric Antigen Receptor T-cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Efficacy, Safety, and Future Directions
Authors:
Open Access
- 31 July 2025
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 17 (7) , e89172
Abstract
Pediatric acute lymphoblastic leukemia (ALL) poses significant treatment challenges, particularly in relapsed or refractory cases. This review synthesizes recent studies evaluating the safety and efficacy of chimeric antigen receptor T (CAR-T) cell therapy, specifically tisagenlecleucel, in achieving complete remission (CR) and improving overall survival rates among pediatric patients with ALL. A comprehensive literature search identified 12 studies published between January 2014 and July 2024, encompassing cohort studies and clinical trials. Findings indicate that CAR-T cell therapy demonstrates superior CR rates (up to 100% in some studies) and manageable safety profiles, with common adverse effects, including cytokine release syndrome (CRS) and neurotoxicity. This review points out some of the important aspects such as the identification of biomarkers for response prediction, understanding of the mechanisms of resistance, and the crucial requirement for long-term outcome data. Challenges remain in the management of adverse effects, particularly CRS and neurotoxicity. This review underscores the transformative potential of CAR-T cell therapy in pediatric oncology while emphasizing critical areas for further investigation to optimize patient outcomes and enhance the therapeutic landscape for pediatric ALL.Keywords
This publication has 24 references indexed in Scilit:
- Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging TransplantationClinical Lymphoma Myeloma and Leukemia, 2024
- CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trialNature Medicine, 2021
- Genetics and prognosis of ALL in children vs adultsHematology-American Society Hematology Education Program, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Tragedy, Perseverance, and Chance — The Story of CAR-T TherapyNew England Journal of Medicine, 2017
- Acute Lymphoblastic Leukemia in ChildrenNew England Journal of Medicine, 2015
- Biology of Childhood Acute Lymphoblastic LeukemiaPediatric Clinics of North America, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trialThe Lancet Oncology, 2013
- Acute lymphoblastic leukaemiaThe Lancet, 2008